These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 19089739)

  • 1. Triple-negative/basal-like breast cancer: review.
    Rakha EA; Ellis IO
    Pathology; 2009 Jan; 41(1):40-7. PubMed ID: 19089739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple negative tumours: a critical review.
    Reis-Filho JS; Tutt AN
    Histopathology; 2008 Jan; 52(1):108-18. PubMed ID: 18171422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.
    Karihtala P; Auvinen P; Kauppila S; Haapasaari KM; Jukkola-Vuorinen A; Soini Y
    Breast Cancer Res Treat; 2013 Feb; 138(1):81-90. PubMed ID: 23412770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
    Peng Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.
    Badve S; Dabbs DJ; Schnitt SJ; Baehner FL; Decker T; Eusebi V; Fox SB; Ichihara S; Jacquemier J; Lakhani SR; Palacios J; Rakha EA; Richardson AL; Schmitt FC; Tan PH; Tse GM; Weigelt B; Ellis IO; Reis-Filho JS
    Mod Pathol; 2011 Feb; 24(2):157-67. PubMed ID: 21076464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
    Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer.
    Beltjens F; Molly D; Bertaut A; Richard C; Desmoulins I; Loustalot C; Charon-Barra C; Courcet E; Bergeron A; Ladoire S; Jankowski C; Boidot R; Arnould L
    Int J Cancer; 2021 Jul; 149(1):200-213. PubMed ID: 33634878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance.
    Mohammed RA; Ellis IO; Mahmmod AM; Hawkes EC; Green AR; Rakha EA; Martin SG
    Mod Pathol; 2011 Jun; 24(6):774-85. PubMed ID: 21378756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic triple-negative breast cancer.
    Rakha EA; Chan S
    Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
    Diaz LK; Cryns VL; Symmans WF; Sneige N
    Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective.
    Penault-Llorca F; Viale G
    Ann Oncol; 2012 Aug; 23 Suppl 6():vi19-22. PubMed ID: 23012297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of triple-negative breast cancer.
    Arslan C; Dizdar O; Altundag K
    Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
    Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
    Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
    Kurebayashi J
    Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer.
    Siroy A; Abdul-Karim FW; Miedler J; Fong N; Fu P; Gilmore H; Baar J
    Hum Pathol; 2013 Oct; 44(10):2159-66. PubMed ID: 23845471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo.
    Sharpe R; Pearson A; Herrera-Abreu MT; Johnson D; Mackay A; Welti JC; Natrajan R; Reynolds AR; Reis-Filho JS; Ashworth A; Turner NC
    Clin Cancer Res; 2011 Aug; 17(16):5275-86. PubMed ID: 21712446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.